Herantis Pharma Oyj Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016
August 25, 2016 at 02:00 am EDT
Herantis Pharma Oyj reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported net turnover of EUR 25,291.91 against EUR 1,155.00 a year ago. Operating loss was EUR 2,572,868.67 against EUR 13,730,577.13 a year ago. Loss before extraordinary items was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Loss before appropriations and taxes was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Consolidated loss was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Cash flow used in operating activities was EUR 2,113,037.51 against EUR 5,335,813.11 a year ago. Investments on tangible and intangible assets were EUR 6,588.61. Loss per share was EUR 0.63 compared with EUR 3.34 a year ago.
The company does not expect essential revenue in 2016.